Featured Clinical Studies
Standing Strong: A Study for People with Chronic Kidney Disease
Researchers at Purdue University are studying why some people with chronic kidney disease (CKD) may be more likely to lose their balance or fall.People with CKD can sometimes have changes in their bones, blood vessels, or brain that may affect strength, balance, or walking. We want to learn more about …
Discover a New Path to Hope: Join a Study That’s Working to Improve Care for Depression
Take the First Step Toward Feeling Better—Join Our Depression Study Today!Living with depression can feel heavy, even on your best days. If you’re looking for new options—or simply wondering what else might help—you’re not alone. This research study is exploring a possible new treatment for major depression, and you may …
GLP-1 Medications and Food Experiences Study
Have you recently started a GLP-1? You may qualify for a paid research study to help us learn how weight loss medications affect taste, appetite, and food choices.Our study is exploring how certain weight-loss medications may affect how adults with obesity experience food. These medications, known as GLP-1 receptor agonists, …
Browse by Featured categories
Aging
Children, Families & Pregnancy
Dental
Online
Alcohol, Tobacco, and Substance Use
Alzheimer’s Disease & Dementia
Asthma,Lungs & Allergies
Bones, Muscles and Joints
Brain, Spine & Nervous System
Covid-19 & Infectious Disease
Diabetes, Heart and Blood Vessels
Digestive System (GI), Bowel & Liver
Health Mental, Behavioral Health & Developmental Conditions
Healthy Volunteer
Cancer
Diet, Nutrition, Exercise, & Sleep
Browse by Featured categories
Aging
Children, Families & Pregnancy
Dental
Online
Alcohol, Tobacco, or Other Substance Use
Alzheimer’s Disease & Dementia
Asthma,Lungs & Allergies
Bones, Muscles and Joints
Brain, Spine & Nervous System
Covid-19 & Infectious Disease
Diabetes, Heart and Blood Vessels
Digestive System (GI), Bowel & Liver
Health Mental, Behavioral Health & Developmental Conditions
Healthy Volunteer
Cancer
Diet, Nutrition, Exercise, & Sleep
Browse by Featured categories
Aging
Alcohol, Tobacco and Substance Use
Brain, Spine and Nerves
Cancer
Diabetes
Diet, Exercise and Nutrition
Healthy Volunteers
Mental and Behavioral Health
Alzheimer’s Disease and Dementia
Autoimmune Disease
Bladder and Kidneys
Bones, Muscles and Joints
Community and Environmental Health
Dental
Eye Conditions
Genetic and Rare Conditions
GI, Liver and Pancreas
Hearing, Speech and Language
Heart Health
Infectious Disease
Lungs, Asthma and Allergies
Maternal, Infant and Child Health
Online Studies
Public Health Studies
Skin and Wounds
Sleep
Surgery, Transplant and Imaging
Thyroid, Hormones and Metabolism
Help Shape the Future of Health
with the Indiana Biobank
By donating a small blood sample, you can help researchers discover better treatments and improve health across Indiana.
Who Can Join?
All IU Health Patients of Any Age
What Is Involved?
It's easy-we collect a blood sample during your regular doctor visit.
Why does it Matter?
By taking part, you're helping improve care for you, your loved ones, and people across Indiana.
Recently added/updated trials
Preember: A Phase 2, Open-Label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, Her2-Negative Breast Cancer
R
Rina Yadav
Cohort 1: - Assess the effect of imlunestrant versus tamoxifen on tumor cell proliferation (Ki-67). - Assess the effect of imlunestrant versus imlunestrant + goserelin on tumor cell proliferation (Ki-67).Cohort 2: - Assess the rate of symptomatic or complex ovarian cysts with imlunestrant treatment without OFS.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact the IU Clinical Trials Office at:Email: iutrials@iu.edu Phone: (317) 278-5632
A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (Psma) Positron Emission Tomography (Pet) Combined With Magnetic Resonance Imaging (Mri) Compared to Standard of Care (Soc) for the Detection of Prostate Cancer (Pca).
C
Clinton Bahler, MD
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office:Email: iutrials@iu.edu Phone: (317) 278-5632
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
J
Jennifer King
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632
PATIENTS PERSPECTIVES ON TREATMENT DECISION-MAKING AND THE ACCEPTABILITY AND USABILITY OF THE INTERACTIVE WEB-ENABLED COMMUNICATION RESOURCES OF THE CLL/SLL CARE ROAD MAP
L
Larry Cripe, MD
The purpose of the study is to understand how people think about choosing between two or more treatment options and then to seek their reactions to the CLL Mind Map and Patient First Resources. Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact theIU Clinical Trials Office at :Email: iutrials@iu.edu Phone: (317) 278-5632
How Do You Move? Participants Needed for MRI Study
Alexandra Moussa-Tooks
Why is this study being done?The purpose of this study is to understand how movement and sensory characteristics (e.g., posture, walking, hand and arm based reaching) present in psychotic disorders over time. Who can take part?We are looking for individuals, ages 18-55, who have been diagnosed with Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, or any other type of psychotic disorder.
Healthy Adults Needed for MRI Study of Movement and Brain Function
Alexandra Moussa-Tooks
Why is this study being done?The purpose of this study is to understand how movement and sensory characteristics (e.g., posture, walking, hand and arm based reaching) present in psychotic disorders over time. Who can take part?We are looking for healthy individuals, ages 18-55, who have never been diagnosed with psychosis.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ly4064809 Combined with a Cdk4/6 Inhibitor and Endocrine Therapy in Adults with Hr+, Her2- Advanced Breast Cancer with a Pik3Ca Mutation Who Received No Prior Treatment for Advanced Breast Cancer (Pikalo-2)
T
Tarah Ballinger, MD
The purpose of the study is to assess the efficacy and safety of the addition of LY4064809 to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects. Participants must have breast cancer that has a mutation in the PIK3CA gene. Participants must have breast cancer that has spread to other parts of the body and that expresses hormone receptors but not HER2 receptors. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632
